vs

Side-by-side financial comparison of BigBear.ai Holdings, Inc. (BBAI) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

BigBear.ai Holdings, Inc. is the larger business by last-quarter revenue ($27.3M vs $13.7M, roughly 2.0× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-22.1M).

BigBear.ai Holdings, Inc. develops and delivers artificial intelligence-powered decision support and analytics solutions. Its core offerings cover predictive analytics, supply chain optimization, and operational intelligence platforms, serving key segments including national defense, intelligence agencies, and commercial enterprise clients primarily across North America, helping customers improve operational efficiency and mitigate risks.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

BBAI vs XLO — Head-to-Head

Bigger by revenue
BBAI
BBAI
2.0× larger
BBAI
$27.3M
$13.7M
XLO
More free cash flow
XLO
XLO
$20.0M more FCF
XLO
$-2.1M
$-22.1M
BBAI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BBAI
BBAI
XLO
XLO
Revenue
$27.3M
$13.7M
Net Profit
$10.4M
Gross Margin
20.3%
Operating Margin
-295.0%
-86.5%
Net Margin
75.7%
Revenue YoY
-37.7%
Net Profit YoY
179.1%
EPS (diluted)
$0.17
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBAI
BBAI
XLO
XLO
Q4 25
$27.3M
$13.7M
Q3 25
$33.1M
$19.1M
Q2 25
$32.5M
$8.1M
Q1 25
$34.8M
$2.9M
Q4 24
$43.8M
Q3 24
$41.5M
Q2 24
$39.8M
Q1 24
$33.1M
Net Profit
BBAI
BBAI
XLO
XLO
Q4 25
$10.4M
Q3 25
$2.5M
$-16.3M
Q2 25
$-228.6M
$-15.8M
Q1 25
$-62.0M
$-13.3M
Q4 24
Q3 24
$-15.1M
Q2 24
$-14.4M
Q1 24
$-127.8M
Gross Margin
BBAI
BBAI
XLO
XLO
Q4 25
20.3%
Q3 25
22.4%
Q2 25
25.0%
Q1 25
21.3%
Q4 24
37.4%
Q3 24
25.9%
Q2 24
27.8%
Q1 24
21.1%
Operating Margin
BBAI
BBAI
XLO
XLO
Q4 25
-295.0%
-86.5%
Q3 25
-66.0%
-10.1%
Q2 25
-278.1%
-177.7%
Q1 25
-61.0%
-472.7%
Q4 24
-18.6%
Q3 24
-25.4%
Q2 24
-41.9%
Q1 24
-296.1%
Net Margin
BBAI
BBAI
XLO
XLO
Q4 25
75.7%
Q3 25
7.6%
-85.4%
Q2 25
-704.0%
-196.0%
Q1 25
-178.3%
-452.7%
Q4 24
Q3 24
-36.5%
Q2 24
-36.3%
Q1 24
-385.8%
EPS (diluted)
BBAI
BBAI
XLO
XLO
Q4 25
$0.17
$-3.74
Q3 25
$-0.03
$-0.11
Q2 25
$-0.71
$-0.16
Q1 25
$-0.25
$-0.18
Q4 24
$-0.47
Q3 24
$-0.06
Q2 24
$-0.06
Q1 24
$-0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBAI
BBAI
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$87.1M
$137.5M
Total DebtLower is stronger
$107.0M
Stockholders' EquityBook value
$611.9M
$35.3M
Total Assets
$894.5M
$154.7M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBAI
BBAI
XLO
XLO
Q4 25
$87.1M
$137.5M
Q3 25
$456.6M
$103.8M
Q2 25
$390.8M
$121.6M
Q1 25
$107.6M
$89.1M
Q4 24
$50.1M
Q3 24
$65.6M
Q2 24
$72.3M
Q1 24
$81.4M
Total Debt
BBAI
BBAI
XLO
XLO
Q4 25
$107.0M
Q3 25
$104.9M
Q2 25
$103.0M
Q1 25
$101.4M
Q4 24
$136.2M
Q3 24
$195.7M
Q2 24
$195.7M
Q1 24
$195.6M
Stockholders' Equity
BBAI
BBAI
XLO
XLO
Q4 25
$611.9M
$35.3M
Q3 25
$610.0M
$-8.1M
Q2 25
$266.6M
$7.1M
Q1 25
$197.8M
$10.7M
Q4 24
$-3.7M
Q3 24
$127.5M
Q2 24
$134.7M
Q1 24
$143.2M
Total Assets
BBAI
BBAI
XLO
XLO
Q4 25
$894.5M
$154.7M
Q3 25
$919.8M
$133.7M
Q2 25
$599.4M
$133.8M
Q1 25
$396.3M
$103.7M
Q4 24
$343.8M
Q3 24
$354.1M
Q2 24
$360.9M
Q1 24
$377.6M
Debt / Equity
BBAI
BBAI
XLO
XLO
Q4 25
0.17×
Q3 25
0.17×
Q2 25
0.39×
Q1 25
0.51×
Q4 24
Q3 24
1.54×
Q2 24
1.45×
Q1 24
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBAI
BBAI
XLO
XLO
Operating Cash FlowLast quarter
$-21.8M
$-2.0M
Free Cash FlowOCF − Capex
$-22.1M
$-2.1M
FCF MarginFCF / Revenue
-80.9%
-15.3%
Capex IntensityCapex / Revenue
0.9%
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$-42.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBAI
BBAI
XLO
XLO
Q4 25
$-21.8M
$-2.0M
Q3 25
$-9.6M
$-17.5M
Q2 25
$-3.9M
$-14.5M
Q1 25
$-6.7M
$29.0M
Q4 24
$-14.8M
Q3 24
$-1.9M
Q2 24
$-7.1M
Q1 24
$-14.4M
Free Cash Flow
BBAI
BBAI
XLO
XLO
Q4 25
$-22.1M
$-2.1M
Q3 25
$-9.8M
Q2 25
$-3.9M
$-14.9M
Q1 25
$-6.7M
$29.0M
Q4 24
$-15.0M
Q3 24
$-2.0M
Q2 24
$-7.2M
Q1 24
$-14.4M
FCF Margin
BBAI
BBAI
XLO
XLO
Q4 25
-80.9%
-15.3%
Q3 25
-29.5%
Q2 25
-11.9%
-184.0%
Q1 25
-19.4%
988.3%
Q4 24
-34.2%
Q3 24
-4.9%
Q2 24
-18.1%
Q1 24
-43.5%
Capex Intensity
BBAI
BBAI
XLO
XLO
Q4 25
0.9%
0.7%
Q3 25
0.6%
0.0%
Q2 25
0.0%
5.0%
Q1 25
0.2%
0.8%
Q4 24
0.4%
Q3 24
0.3%
Q2 24
0.3%
Q1 24
0.1%
Cash Conversion
BBAI
BBAI
XLO
XLO
Q4 25
-0.19×
Q3 25
-3.80×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons